General anesthetics

Ehave Inc. Files for KetaDash Trademark and to Uplist its Shares to the OTCQB

Retrieved on: 
Wednesday, March 3, 2021
Drugs, Psychoactive drugs, Neurochemistry, Dissociative drugs, General anesthetics, Sedatives, Antidepressants, Nicotinic antagonists, Ketamine

Ehave recently announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology.

Key Points: 
  • Ehave recently announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology.
  • On March 1, 2021 Ehave successfully filed its application to uplist its shares on the OTCQB market.
  • The KetaDASH www.ketadash.com platform allows licensed ketamine clinics and patients who have been prescribed ketamine by a physician to administer the treatment at home intravenously.
  • Ben Kaplan, Chief Executive Officer of Ehave commented, The application for a U. S. Trademark is a key step in protecting our valuable brand and psychedelic medicine assets, most notably KetaDASH.

The Ketamine Healing Clinic of Los Angeles Offers the Advanced Fibromyalgia Treatment Protocol for Fibromyalgia Sufferers

Retrieved on: 
Wednesday, February 24, 2021
Drugs, Psychoactive drugs, Neurochemistry, General anesthetics, Rheumatology, Amines, Ketamine, Fibromyalgia

There is no known cure for fibromyalgia, yet the Advanced Fibromyalgia Protocol offered at the Ketamine Healing Clinic of Los Angeles has proven to be effective in treating its multiple symptoms.

Key Points: 
  • There is no known cure for fibromyalgia, yet the Advanced Fibromyalgia Protocol offered at the Ketamine Healing Clinic of Los Angeles has proven to be effective in treating its multiple symptoms.
  • He founded The Ketamine Healing Clinic of Los Angeles in 2014 after noticing the profound mental health benefits ketamine treatments can provide.
  • If you are suffering from fibromyalgia, chronic pain, or a mood condition, visit the Ketamine Healing Clinic of Los Angeles' website at http://www.ketaminehealing.com , or contact the clinic at (866) 987-7874.
  • Dr. David Mahjoubi, Ketamine Healing Clinic of Los Angeles, (424) 278-4241, [email protected]

Addex GABAB Positive Allosteric Modulator Demonstrates Promise in Alcohol Use Disorder

Retrieved on: 
Tuesday, February 16, 2021
Branches of biology, Receptor agonists, Neurochemistry, GABAA receptor positive allosteric modulators, Drinking culture, Sedatives, Hypnotics, General anesthetics, Alcohol, Allosteric modulator, gamma-Aminobutyric acid, Allosteric regulation

ADX71441 potently decreased binge-like drinking, reduced relapse-like drinking, and dose-dependently reduced alcohol self-administration as well as decreasing motivation to consume alcohol.

Key Points: 
  • ADX71441 potently decreased binge-like drinking, reduced relapse-like drinking, and dose-dependently reduced alcohol self-administration as well as decreasing motivation to consume alcohol.
  • Augier E. (2021) Recent Advances in the Potential of Positive Allosteric Modulators of the GABAB Receptor to Treat Alcohol Use Disorder.
  • (2014) Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice.
  • (2017) The GABAB positive allosteric modulator ADX71441 attenuates alcohol self-administration and relapse to alcohol seeking in rats.

Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate

Retrieved on: 
Tuesday, February 9, 2021
Drugs, Psychoactive drugs, Medical specialties, General anesthetics, Anesthesia, GABAA receptor positive allosteric modulators, Analgesics, Euphoriants, Sedation, Midazolam, Ketamine, Opioid

We are pleased with the results of our Phase 1 MELT study, which marks another important milestone for the Company, said Greg Madison, CEO of Melt Pharmaceuticals.

Key Points: 
  • We are pleased with the results of our Phase 1 MELT study, which marks another important milestone for the Company, said Greg Madison, CEO of Melt Pharmaceuticals.
  • MELT is a patented combination of midazolam and ketamine in a rapidly dissolving, sublingual tablet to provide sedation and analgesia for patients undergoing cataract surgery.
  • This needle-free and opioid-free approach seeks to replace the current practice of IV-delivered sedation medication for patients.
  • Melts core technology is a series of combination non-opioid sedation drug formulations that may replace or supplement current sedation modalities for more than 100 million medical procedures in the United States.

US General Anesthesia Drugs Market worth $2.4 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, February 4, 2021
Drugs, Medical specialties, Receptor agonists, Anesthesia, General anesthetics, GABAA receptor positive allosteric modulators, Sedatives, Nicotinic antagonists, Propofol, General anaesthesia, Ketamine, Benzodiazepine

Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.

Key Points: 
  • Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.
  • Similarly, intravenous anesthesia drugs are further categorized into propofol, benzodiazepines, ketamine, methohexital sodium and others intravenous general anesthesia drugs.
  • General intravenous anesthesia drugs are less expensive and do not require expensive machines for administration which contributes to the high market share of the segment.
  • Based on end user, the US general anesthesia drugs market has been segmented into hospitals and ambulatory surgery centers.

US General Anesthesia Drugs Market worth $2.4 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, February 4, 2021
Drugs, Medical specialties, Receptor agonists, Anesthesia, General anesthetics, GABAA receptor positive allosteric modulators, Sedatives, Nicotinic antagonists, Propofol, General anaesthesia, Ketamine, Benzodiazepine

Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.

Key Points: 
  • Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.
  • Similarly, intravenous anesthesia drugs are further categorized into propofol, benzodiazepines, ketamine, methohexital sodium and others intravenous general anesthesia drugs.
  • General intravenous anesthesia drugs are less expensive and do not require expensive machines for administration which contributes to the high market share of the segment.
  • Based on end user, the US general anesthesia drugs market has been segmented into hospitals and ambulatory surgery centers.

MD Infusions Grand Opening Brings Revolutionary Treatment Center to Northbrook, Illinois

Retrieved on: 
Monday, February 1, 2021
Drugs, Psychoactive drugs, Neurochemistry, General anesthetics, Amines, Ketamine

They are uniquely qualified to sustain patients' quality of life, specializing in several infusions, namely ketamine therapy, NAD+ infusions and IV vitamin infusions.

Key Points: 
  • They are uniquely qualified to sustain patients' quality of life, specializing in several infusions, namely ketamine therapy, NAD+ infusions and IV vitamin infusions.
  • Dr. Evan Laskaris, Dr. Richard Aronwald and Dr. Tim Heilenbach are the founders of MD Infusions.
  • In addition to Ketamine therapy, MD Infusions offers NAD+ infusions and IV vitamin infusions.
  • The MD Infusions team is enthusiastic about opening their new practice and providing patients with revolutionary alternatives that prioritize safety and effectiveness, while delivering their infusions in a relaxing and comfortable environment.

DGAP-News: PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS

Retrieved on: 
Thursday, January 28, 2021
Drugs, Chemical compounds, Organic compounds, GABAA receptor positive allosteric modulators, Anesthesia, Benzodiazepines, Pyridines, Remimazolam, General anesthetics, Sedation, Procedural sedation and analgesia, Ketamine, remimazolam, PAION

PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS

Key Points: 
  • PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
    The issuer is solely responsible for the content of this announcement.
  • BYFAVO(TM) was approved by the U.S. Food and Drug Administration (FDA) on 2 July 2020 for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.
  • Remimazolam is approved in the U.S. and China for procedural sedation and in Japan and South Korea for general anesthesia.
  • In Europe, PAION submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in procedural sedation in November 2019.

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation Targeting Mental Health, Neurological and Pain Disorders

Retrieved on: 
Tuesday, January 19, 2021
Drugs, Psychoactive drugs, Neurochemistry, NMDA receptor antagonists, General anesthetics, Amines, Chloroarenes, Nicotinic antagonists, Ketamine, Sedation, Mental disorder

We believe KETABET has the potential to change the way mental health, neurological and pain disorders will be treated for the hundreds of millions of people globally who are suffering from these debilitating conditions, said Fabio Chianelli, CEO of PharmaTher.

Key Points: 
  • We believe KETABET has the potential to change the way mental health, neurological and pain disorders will be treated for the hundreds of millions of people globally who are suffering from these debilitating conditions, said Fabio Chianelli, CEO of PharmaTher.
  • We are pursuing the clinical development of KETABET to overcome the current limitations of ketamine and to unlock the known potential therapeutic value of ketamine for FDA approval.
  • Ketamine was approved by the FDA in 1970 and is clinically used for analgesia, sedation, and anesthetic induction.
  • These range from the common problems such as aging, cancer, infectious diseases, mental disorders, occupational diseases, to health policy.

Study on Patented Non-Opioid MKO Melt® Reported in Leading Peer-Reviewed Anesthesia Journal

Retrieved on: 
Thursday, December 3, 2020
Medical specialties, Drugs, Clinical medicine, Anesthesia, General anesthetics, GABAA receptor positive allosteric modulators, Analgesics, Synthetic opioids, Fentanyl, Midazolam, Sedation

NASHVILLE, Tenn., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that a study featuring its patented MKO Melt formulation has been published in the American Association of Nurse Anesthetists (AANA) Journal.

Key Points: 
  • NASHVILLE, Tenn., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that a study featuring its patented MKO Melt formulation has been published in the American Association of Nurse Anesthetists (AANA) Journal.
  • The IRB-approved study compared the effectiveness and equivalency of a sublingual compounded non-opioid MKO Melt troche during monitored anesthesia sedation with traditional IV sedation for maintaining comfort in patients undergoing cataract surgery.
  • One group received IV sedation consisting of fentanyl and midazolam (n=54) and the other group received sublingual MKO Melt (n=53).
  • The authors of the study reported no financial relationships with any commercial related entity connected to the study.